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Abstract
Background: Although methicillin-susceptible Staphylococcus aureus (MSSA) native bone and joint infection (BJI)
constitutes the more frequent clinical entity of BJI, prognostic studies mostly focused on methicillin-resistant S.
aureus prosthetic joint infection. We aimed to assess the determinants of native MSSA BJI outcomes.
Methods: Retrospective cohort study (2001–2011) of patients admitted in a reference hospital centre for native
MSSA BJI. Treatment failure determinants were assessed using Kaplan-Meier curves and binary logistic regression.
Results: Sixty-six patients (42 males [63.6%]; median age 61.2 years; interquartile range [IQR] 45.9–71.9) presented
an acute (n = 38; 57.6%) or chronic (n = 28; 42.4%) native MSSA arthritis (n = 15; 22.7%), osteomyelitis (n = 19;
28.8%) or spondylodiscitis (n = 32; 48.5%), considered as “difficult-to-treat” in 61 cases (92.4%). All received a
prolonged (27.1 weeks; IQR, 16.9–36.1) combined antimicrobial therapy, after surgical management in 37 cases
(56.1%). Sixteen treatment failures (24.2%) were observed during a median follow-up period of 63.3 weeks (IQR,
44.7–103.1), including 13 persisting infections, 1 relapse after treatment disruption, and 2 super-infections.
Independent determinants of treatment failure were the existence of a sinus tract (odds ratio [OR], 5.300; 95%
confidence interval [CI], 1.166–24.103) and a prolonged delay to infectious disease specialist referral (OR, 1.134;
95% CI 1.013–1.271).
Conclusions: The important treatment failure rate pinpointed the difficulty of cure encountered in complicated
native MSSA BJI. An early infectious disease specialist referral is essential, especially in debilitated patients or in
presence of sinus tract.
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Background
Bone and joint infections (BJIs) constitute difficult-to-
treat clinical entities, known to be associated to signifi-
cant morbidity and mortality rates. Most of the current
literature on BJI concerns orthopaedic device infections
and/or methicillin-resistant Staphylococcus aureus (MRSA).
However, native infections represent the most frequent
clinical form of BJI, accounting for approximately 70% of
cases, and are mainly caused by methicillin-susceptible
Staphylococcus aureus (MSSA) [1]. With a respective inci-
dence of 4–10, 10 and 2.4 per 100,000 person-year, septic
arthritis, osteomyelitis and vertebral osteomyelitis are asso-
ciated with a mortality rate of 2-10%, and a risk of perman-
ent loss of joint function of 40% [2,3]. It has recently been
shown that the setting of a systematic infectious disease
specialist consultation in a septic orthopaedic surgery unit
allows a better adjustment of empirical antimicrobial ther-
apy [4]. However, risk factors for treatment failure have
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poorly been studied. We addressed this question in a retro-
spective cohort study.
Methods
All patients with native MSSA BJI were enrolled in a
monocentric retrospective cohort study (2001–2011) in
the reference center for the management of complex BJI
of the Lyon University Hospitals, France. To be included,
patients should present clinical evidences of infection and
at least one reliable bacteriological sample positive for
MSSA including percutaneous joint fluid aspiration, surgi-
cal sample, and/or blood culture, excluding patients with
diabetic foot- and decubitus ulcer-related BJI because of
the specific management of these infections. The time
from initiation of symptoms of infection to diagnosis de-
fined acute (infection lasting for ≤ 4 weeks) and chronic
(infection lasting for > 4 weeks) infections [5]. The modi-
fied Charlson comorbidity index was calculated as previ-
ously described [6]. Immunosuppression was defined as: i)
steroid therapy > 10 mg of prednisone per day or equiva-
lent; ii) immunosuppressive drug during the two last
months before BJI onset; or iii) chemotherapy. Treatment
failure included i) persisting infection under appropriate
antimicrobial therapy; and/or ii) relapse after antimicrobial
therapy disruption.
Data were collected from medical records, nursing
charts and biological software in an anonymous standard-
ized case report form. Frequencies of the study variables
were described as effectives (%) for dichotomous variables,
and medians (interquartile range [IQR]) for continuous
values. For the percentage calculation of each variable, the
number of missing values was excluded from the denom-
inator. Non-parametric statistical methods were used to
compare the study groups (Khi2, Fisher exact test, Mann–
Whitney U test), as appropriate. Kaplan-Meier curves
were compared between groups using the log-rank test.
Stepwise binary logistic regression was used to determine
risk factors for treatment failure. After checking variables
for interactions, variables with medical meaning and p
values obtained in univariate analysis < 0.15 were included
in the final multivariate model. A value of p < 0.05 was
taken as significant. All analyses were performed using
SPSS software version 17.0 (SPSS, Chicago, IL).
This study received the approval of the French South-
East ethics committee with the reference number
CAL2011-21. In accordance with the French legislation,
written informed patient consent was not required for any
part of the study.
Results
After exclusion of 4 diabetic foot- or decubitus ulcer-
related infections and 7 patients with numerous missing
values, 66 patients were enrolled in the analysis (42 males;
63.6%), with a median age of 61.2 years (IQR, 45.9–71.9).
Demographic characteristics, comorbidities and BJI pres-
entation are summarized in Table 1. Of note, 61 (92.4%)
of included BJI were considered as difficult-to-treat, in-
cluding chronic BJI (n = 28; 42.4%), local abscess (n = 33;
50.0%), sinus tract (n = 18; 27.3%), bacteraemia (n = 35;
53.0%) and/or associated infective endocarditis (n = 4;
6.1%). Importantly, in comparison with arthritis, osteo-
myelitis were more often chronic (n = 16 (84.2%) versus
n = 2 (13.3%); p < 10−3), and sinus tract (n = 13 (68.4%)
versus n = 2 (13.3%); p = 0.002) and abscesses (n = 10
(52.6%) versus n = 2 (13.3%); p = 0.030) were more
frequent.
A surgical management was performed in 37 cases
(56.1%). All patients received antimicrobial therapy for
27.1 weeks (IQR, 16.9–36.1), initially administrated
intravenously in 59 patients (89.4%) for 7.1 weeks (IQR,
4.9–11.7). All patients received a combined antistaphylo-
coccal therapy during almost all treatment duration
(25.6 weeks; IQR, 15.0-32.1). The antimicrobial were
chosen according to recommendations and microbio-
logical susceptibility testing in all cases, with respect of
contraindications (i.e., drug interactions, previous ad-
verse events …). The main used molecules, doses and
duration are presented in Table 2. Of note, 25 patients
(37.9%) received glycopeptides, given as initial empirical
therapy (n = 4; for a total duration ≤ 14 days), a previous
allergic reaction to other antistaphylococcal antibiotics
(n = 12), a polymicrobial infection (n = 5), or difficult ven-
ous access (n = 4, then using subcutaneous teicoplanin).
Treatment failure was observed in 16 cases (24.2%)
during a median follow-up period of 63.3 weeks (IQR,
44.7–103.1): i) 13 patients (19.7%) with persistent infec-
tion including 9 patients requiring new surgery per-
formed in a delay of 11.6 weeks (IQR, 5.3–25.6) after
antimicrobial treatment initiation; ii) one relapse occur-
ring 13.7 weeks after treatment disruption; and iii) 2
super-infections (one with Staphylococcus epidermidis,
and one with Enterococcus faecalis and Streptococcus
intermedius). Final evolution was favourable in 12 of the
16 patients with initial treatment failure. Three patients
had to be amputated. Five patients (7.6%) died during
follow-up, without sepsis-related death. Of note, one fatal
pulmonary embolism linked with prolonged bed rest
occurred. At the end of follow-up, 24 patients (38.1%)
presented functional sequels, consisting in chronic pain
and/or loss of function.
Patients presenting a treatment failure did not differ
from those with favourable outcome regarding their base-
line characteristics, with the exception of a higher preva-
lence of diabetes (37.5% versus 10%; p = 0.018) and a
higher number of patients presenting a modified Charlson
comorbidity index > 2 (75.0% versus 44.0%; p = 0.044).
There was no difference between the two groups regarding
the use of the main administered antimicrobials (Table 2).
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Table 1 Patient’s characteristics and risk factors for native methicillin-susceptible Staphylococcus aureus bone and joint
infection treatment failure
Risk factor for treatment failure Total (n = 66) Treatment failure
(n = 16)
Favourable




Sex (male) 42 (63.6%) 10 (62.5%) 32 (64.0%) 0.913 0.938 (0.292-3.006) 0.938
Age (years) 61.2 (45.9-71.9) 61.2 (48.5-69.6) 60.4 (43.5-76.5) 0.828 1.119 (0.820-1.525)* 0.479
Comorbidity
Modified Charlson score 3.0 (0.0-5.0) 4.0 (2.5-5.0) 2.0 (0.0-4.0) 0.163 1.093 (0.907-1.318) 0.351
Modified Charlson score > 2 34 (51.5%) 12 (75.0%) 22 (44.0%) 0.044 3.818 (1.081-13.486) 0.037
Obesity (BMI > 30 kg/m2) 13 (20.0%) 3 (20.0%) 10 (20.0%) 1.000 1.000 (0.236-4.231) 1.000
Denutrition (BMI < 18 kg/m2) 3 (4.6%) 1 (6.7%) 2 (4.0%) 1.000 1.714 (0.145-20.332) 0.669
Diabetes 11 (16.7%) 6 (37.5%) 5 (10.0%) 0.018 5.400 (1.372-21.260) 0.016
Immunodepression 8 (12.1%) 3 (18.8%) 5 (10.0%) 0.390 2.077 (0.437-9.871) 0.358
Nephropathy 10 (15.2%) 3 (18.8%) 7 (14.0%) 0.695 1.418 (0.320-6.277) 0.646
Hepatopathy 2 (3.0%) 2 (12.5%) 0 (0%) 0.056 NC NC
Chronic pulmonary disease 12 (18.2%) 4 (25.0%) 8 (16.0%) 0.465 1.750 (0.449-6.825) 0.420
Chronic heart failure 5 (7.6%) 0 (0%) 5 (10.0%) 0.325 NC NC
Chronic inflammatory disease 7 (10.6%) 2 (12.5%) 5 (10.0%) 1.000 1.286 (0.224-7.370) 0.778
Neoplasm, hemopathy 7 (10.6%) 1 (6.3%) 6 (12.0%) 0.674 0.489 (0.054-4.397) 0.523
Dementia 1 (1.5%) 1 (6.3%) 0 (0%) 0.242 NC NC
BJI type
Arthritis 15 (22.7%) 3 (18.8%) 12 (24.0%) 0.747 0.731 (0.178-3.003) 0.731
Osteomyelitis 19 (28.8%) 8 (50.0%) 11 (22.0%) 0.054 3.545 (1.082-11.615) 0.037
Vertebral osteomyelitis 32 (48.5%) 5 (31.3%) 27 (54.0%) 0.195 0.387 (0.117-1.279) 0.120
BJI mechanism
Haematogenous 40 (60.6%) 8 (50.0%) 32 (64.0%) 0.480 0.563 (0.180-1.754) 0.321
Inoculation 22 (33.3%) 7 (43.8%) 15 (30.0%) 0.475 1.815 (0.570-5.779) 0.313
Contiguity 4 (6.1%) 1 (6.3%) 3 (6.0%) 1.000 1.044 (0.101-10.806) 0.971
BJI diagnosis
Fever 43 (65.2%) 10 (62.5%) 33 (66.0%) 1.000 0.859 (0.267-2.764) 0.798
Fistula 18 (27.3%) 7 (43.8%) 11 (22.0%) 0.112 2.758 (0.836-9.092) 0.096
Abscess 33 (50.0%) 7 (43.8%) 26 (52.0%) 0.775 0.718 (0.231-2.229) 0.566
Chronic BJI (evolution > 4 weeks) 28 (42.4%) 8 (50.0%) 20 (40.0%) 0.680 1.500 (0.484-4.651) 0.483
Delay from symptoms to diagnosis (weeks) 2.1 (0.0-10.3) 2.6 (0.0-34.4) 2.1 (0.5-9.8) 0.905 1.026 (0.996-1.057) 0.095
Polymicrobial BJI 10 (15.2%) 3 (18.8%) 7 (14.0%) 0.695 1.418 (0.320-6.277) 0.646
Infective endocarditis 4 (6.1%) 0 (0%) 4 (8.0%) 0.565 NC NC
Biological inflammatory syndrome 58 (87.9%) 16 (100%) 42 (84.0%) 0.183 NC NC
Maximal CRP value (mg/L) 152.7 (52.0-317.8) 145.0 (75.3-317.3) 154.7 (52.0-325.9) 0.994 1.000 (0.996-1.004) 0.931
Maximal WBC count value (/mm3) 10,200 (7,720-14,920) 11,000 (10,200-16,280) 9,710 (7,350-14,770) 0.100 1.058 (0.961-1.164) 0.251
Maximal neutrophil count value (/mm3) 7,600 (5,200-11,970) 9,300 (6,740-13,470) 7,380 (5,200-11,400) 0.292 1.056 (0.957-1.165) 0.277
Chronic sepsis on pathological examination 9/21 (47.4%) 2/3 (66.7%) 7/16 (43.8%) 0.582 2.571 (0.192-34.473) 0.476
Surgical treatment 37 (56.1%) 11 (68.8%) 26 (52.0%) 0.377 2.031 (0.615-6.701) 0.245
Delay from symptoms to surgery (days) 3 (0–12.5) 0 (0–9) 4 (0–12) 0.402 0.999 (0.994-1.004) 0.632
Antibiotic use
Delay from diagnosis to specialist referral (days) 4.9 (0.0-23.1) 6.3 (0.7-91.0) 4.9 (0.0-18.5) 0.445 1.102 (1.003-1.211) 0.043
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Table 1 Patient’s characteristics and risk factors for native methicillin-susceptible Staphylococcus aureus bone and joint
infection treatment failure (Continued)
i.v.treatment 59 (89.4%) 13 (81.3%) 46 (92.0%) 0.347 0.377 (0.075-1.901) 0.237
i.v.treatment duration (weeks) 7.1 (4.9-11.7) 9.1 (5.3-16.4) 7.0 (4.6-9.4) 0.297 1.037 (0.986-1.091) 0.156
Bitherapy 66 (100%) 16 (100%) 50 (100%) 1.000 NC NC
Bitherapy duration (weeks) 25.6 (15.0-32.1) 27.0 (17.4-38.5) 25.1 (15.1-31.1) 0.533 1.016 (0.983-1.050) 0.345
Initial anti-staphylococcal bitherapy 53 (81.5%) 12 (75.0%) 41 (83.7%) 0.719 0.585 (0.150-2.285) 0.441
Initial anti-MSSA bitherapy 40 (61.5%) 8 (50.0%) 32 (65.3%) 0.480 0.531 (0.169-1.666) 0.278
Biological follow-up
1 month CRP level 13.0 (3.6-36.0) 13.3 (7.4-70.4) 11.0 (3.2-31.9) 0.296 1.006 (0.994-1.018) 0.315
Decrease in CRP level at 1 month < 50% 9 (13.8%) 4 (26.7%) 5 (10.0%) 0.204 3.273 (0.752-14.245) 0.114
1 month CRP level < 10 mg/L 29 (44.6%) 5 (33.3%) 24 (48.0%) 0.377 0.542 (0.162-1.814) 0.320
Results are presented as n (%) for dichotomic variables compared using Chi-square or Fisher exact tests, and median (interquartile range) for continuous variables,
compared using Mann–Whitney U-test. Risk factors for treatment failure were assessed using logistic binary regression.
*For a 10-year increase in age.
BJI, Bone and joint infection; CI, Confidence interval; BMI, Body mass index; CRP, C-reactive protein; i.v., Intravenous; MSSA, Methicillin-susceptible Staphylococcus
aureus; NC, Not calculable; OR, Odds ratio; WBC, White blood cells.
Table 2 Main antimicrobial used in the 66 included patients with native methicillin-susceptible Staphylococcus aureus
native bone and joint infection
All patients (n = 66) Treatment failure (n = 16) Favorable outcome (n = 50) p
i.v anti-staphylococcal penicillin 49 (74.2%) 11 (68.8%) 38 (76.0%) 0.743
Dose (mg/kg/day) 144.6 (133.3-169.0) 141.2 (133.3-150.0) 144.9 (133.6-172.7) 0.606
Duration (weeks) 6.0 (3.0-8.0) 6.7 (4.1-12.2) 5.2 (2.7-7.4) 0.250
Glycopeptides 25 (37.9%) 7 (43.8%) 18 (36.0%) 0.768
Vancomycine, 10 (15.2%) 1 (6.3%) 9 (18.0%) 0.430
Dose (mg/kg/day) 26.0 (20.3-30.5) 25 27.0 (19.2-31.3) NC
Teicoplanin 22 (33.3%) 6 (37.5%) 16 (32.0%) 0.764
Dose (mg/kg/day) 5.7 (4.1-7.0) 7.2 (5.4-8.4) 5.2 (3.9-6.5) 0.197
Duration 3.4 (2.6-7.6) 3.4 (1.9-16.1) 3.9 (2.8-6.7) 0.832
Aminoglycosides 38 (57.6%) 9 (56.3%) 29 (58.0%) 1.000
Rifampin 36 (54.5%) 9 (56.3%) 27 (54.0%) 1.000
Dose (mg/kg/day) 18.8 (14.6-21.2) 18.0 (14.6-21.4) 18.8 (15.2-20.8) 0.841
Duration (weeks) 20.3 (2.7-34.6) 27.5 (11.8-53.1) 16.0 (2.7-25.3) 0.334
Fluoroquinolones 62 (93.9%) 15 (93.8%) 47 (94.0%) 1.000
Ofloxacin dose (mg/kg/day) 6.7 (5.8-7.5) 7.1 (6.3-7.5) 6.35 (5.7-7.3) 0.240
Duration (weeks) 14.6 (8.0-27.6) 17.0 (10.9-31.9) 14.6 (7.6-24.4) 0.397
Macrolid group 46 (69.7%) 10 (62.5%) 36 (72.0%) 0.538
Clindamycin 17 (25.8%) 6 (37.5%) 11 (22.0%) 0.324
Pristinamycin 33 (50.0%) 5 (31.3%) 28 (56.0%) 0.150
Linezolid 6 (9.1%) 1 (6.3%) 5 (10.0%) 1.000
Fucidic acid 4 (6.1%) 1 (6.3%) 3 (6.0%) 1.000
Fosfomycin 13 (19.7%) 4 (25.0%) 9 (18.0%) 0.719
Cotrimoxazole 2 (3.0%) 1 (6.3%) 1 (2.0%) 0.429
i.v: intravenous.
Difference between the two groups were assessed using Chi-square test or Fisher exact test for dichotomic variables, and Mann–Whitney U-test for
continuous variables.
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The delay from diagnosis to infectious disease specialist ad-
vice (i.e. first phone contact, consultation or hospitalization)
tended to have been higher for patients with treatment
failure (6.3 days; IQR, 0.7–91.0; p = 0.445), and especially
for those with persistent infection (7.7 days; IQR, 0.4–
161.0; p = 0.217) than for patients with favourable out-
come. In univariate analysis, diabetes (Odd ratio [OR], 5.4;
95% confidence interval [CI], 1.372–21.260; p = 0.016),
osteomyelitis (OR, 3.545; 95% CI, 1.082–11.615; p = 0.037),
and a prolonged delay for infectious disease specialist refer-
ral (OR, 1.102; 95% CI, 1.003–1.211; p = 0.043) were
associated with treatment failure (Table 1, Figure 1). Non-
interacting and clinically relevant factors included in the
multivariate logistic regression model were a modified
Charlson comorbidity index > 2 (OR, 3.322; 95% CI,
0.753–14.661; p = 0.113), the existence of a sinus tract (OR,
Figure 1 Kaplan-Meier curves for the cumulative risk of treatment failure. Kaplan-Meier curves for the cumulative risk of treatment failure
are presented according to the modified Charlson comorbidity index (panel A), the presence of diabetes (panel B) or sinus tract (panel C), and
the 1-month CRP level (panel D). Groups were compared using the log-rank test.
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5.300; 95% CI, 1.166–24.103; p = 0.031), a delayed referral
to infectious disease specialist (OR, 1.134; 95% CI, 1.013–
1.271; p = 0.029), and a decreased in CRP level at 1 month
< 75% (OR, 3.183; 95% CI, 0.727–13.936; p = 0.124).
Discussion
In this retrospective cohort study including patients with
native MSSA BJI, we pinpointed an important rate of
unfavourable outcome, including a treatment failure rate
reaching one quarter of patients and high proportion of
functional sequels. These results should be interpreted
in light of the high prevalence of difficult-to-treat infec-
tions enrolled in the study, due to the particular recruit-
ment of our institution, a reference centre for the
management of complex BJI. Moreover, the implication
of S. aureus is known to be associated with a poorer out-
come of native and device-associated septic arthritis [7-9].
However, these findings are consistent with the few avail-
able data in the literature [2,10]. Most of studies focusing
on native staphylococcal BJI outcome were large epidemi-
ologic investigations, based on national health surveillance
programs, and consequently not design to assess precise
outcome but only mortality. In a previous study, Wieland
et al. disclosed a treatment failure rate of 12.2% among 41
native MSSA BJI [11]. Although these authors provided
no detailed information about the type of patient recruit-
ment, the short treatment court duration (43 days) and
the low amount of patient requiring nursing home or re-
habilitation facility (11%) allow supposing that common
forms of BJI were more represented. In our particular pa-
tient population requiring long-term antimicrobial ther-
apy, independent risk factors for treatment were the
presence of a sinus tract and a delayed referral to infec-
tious disease specialist. Fistula has already been associated
with poor outcome in prosthetic-joint infection and verte-
bral osteomyelitis [12,13]. Our findings confirmed that
this clinical evidence for chronic infection is associated
with treatment failure of native BJI. Diabetes was associ-
ated with a higher risk of treatment failure in univariate
analysis but was excluded from the final model because
the parameter was included in the Charlson comorbidity
score calculation. However, it is a well-known risk factor
for treatment failure [14]. Interestingly, we observed a
trend in a higher treatment failure rate in bone infections
(50.0%) compared to arthritis (18.8%). This difference
probably lies in the higher rate of chronic infections, sinus
tracts and abscesses among the osteomyelitis cases. Indeed,
in the study by Wieland and colleagues, these two BJI types
harboured the same outcome [11].
The impact of a referral to infectious disease specialist
has been evaluated in several studies, which showed a
benefit in terms of early adaptation of the initial empir-
ical therapy after bacteriological results, and regarding
dosages and duration of antimicrobials [4,15]. However,
these series failed to highlight an improvement of BJI
outcome. Nevertheless, Bauer and colleagues showed a
decrease from 25 to 18% of treatment failure rate after
the instauration of a weekly multidisciplinary staff meet-
ing in their institution, even if this difference was not
significant [15].
Some studies had found other determinants of poor
outcome in native BJI, including advanced age, a raised
white cell count at presentation, the presence of an ab-
scess, a delayed initiation of antimicrobial treatment, a
pre-existing joint disease which may delay diagnosis
[9,13,16-18]. We failed to found any association between
outcome and the nature of antimicrobial therapy, and
especially with the use of glycopeptides used as empirical
therapy, for polymicrobial infection, or in patients with
beta-lactam allergy. Indeed, vancomycin therapy has been
associated with a poor outcome in MSSA bacteraemia,
due to its slow bactericidal activity [19,20]. One study
including a majority of MSSA native osteomyelitis also
suggested that vancomycin-treated infections were nearly
three-times more likely to recur [21]. Contrary to
prosthetic-joint infections, the use of rifampin did not
appear as a protective factor in our study, possibly be-
cause of the less important implication of biofilm in
absence of orthopaedic device. Finally, if the optimal
treatment duration of BJI is unknown, a longer anti-
microbial therapy did not appear as a protective factor.
Prolonged antimicrobial therapy observed in our study is
partly explained by the complicated nature of the included
BJI. Another explanation lies in the retrospective nature of
the study, which included patients in a 10-year period.
Even in the absence of controlled randomized trial, the ab-
sence of evidence regarding the benefit of prolonged treat-
ment lead to progressively decrease treatment duration
in our population, without increasing failure rate over
years (data not shown). Prospective controlled studies
are needed to confirm the feasibility of shorter treatments.
However, some studies had suggested that reducing treat-
ment duration was associated with an increased risk of
treatment failure, notably in vertebral osteomyelitis [22].
Conclusions
MSSA native BJI are associated with a high rate of treat-
ment failure and sequel, despite the use of prolonged
antimicrobial therapy. A multidisciplinary approach is
required, with an early referral to infectious disease spe-
cialist, especially in debilitated patients or in presence of
a sinus tract.
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